#GAMECHANGER. Failure of RA guidelines. 67% of MTX mono fail. Combo DMARDs or scMTX is better #acr17 @rheumnow #443 pic.twitter.com/q4P0fk460V
— Janet (@Janetbirdope) November 8, 2017
No difference in lung safety of Abatacept and TNFI and one study of more ILD with IFX vs ABA #137. #acr17 @rheumnow #526 pic.twitter.com/ugYBF7THKa
— Janet (@Janetbirdope) November 8, 2017
#ACR17 Rheumatology Roundup.Cush #11L biologics #2 CA; #1175 biologics infants; #141 Refractory RA; #1885 Epi of AOSD; #200 Gout Telemedicine ; #885 Voclosporin SLE GN. AKavanaugh #271 CD318; #1205 XRT OA? #661 Entheses; #1112 Pred Gout; #541 SIE; #2031 EMR labs; #144 MVA RA
— Dr. John Cush (@RheumNow) November 8, 2017
84% of cardiac sarcoidosis pts refractory to immunosuppressive tx responded to TNFi. #ACR17 @RheumNow #2904 https://t.co/vTOLfLVjtU
— Dr. Rachel Tate (@uptoTate) November 8, 2017
Dr. Janet Pope: Interstitial Lung Disease and RA
Who should have infliximab? #sarcoidosis #ACR17 pic.twitter.com/JtsKbJivfD
— Christian Ammitzbøll (@cgytz) November 7, 2017
#2127
Successful monoclonal tnfi use in sarcoidosis#ACR17 @rheumnow pic.twitter.com/cwRP8QtEXi— Julio Gonzalez (@japaoli19) November 7, 2017
#ACR17 2864. Unlike RF & ACPA status, anti acetylated Ab pos distinguishes good response to TNFi in RA, and retention pic.twitter.com/OxRw6Pfz7a
— Patrick Kiely (@pkiely500) November 8, 2017
Dr. Julio Gonzalez: Psoriatic Arthritis and AS
Addition of Steroid Rx to bDMARDs increases risk of post op infections. Effect dose depended #ACR17 #2755 @RheumNow pic.twitter.com/gELV2IriLc
— Olga Petryna (@DrPetryna) November 7, 2017
#2453 #acr17 no difference in disease activity&PRO with ADA after MTX d/c at 6mo:LDA 42%ADAvs40%ADA+MTX @RheumNow pic.twitter.com/EtxpmVAQyL
— Olga Petryna (@DrPetryna) November 7, 2017
Dr. Kathryn Dao: FDA Warnings and Precision Medicine
Dr. Janet Pope: Pre-op for Total Hip or Knee Replacements in RA
Anti-TNF drugs could be safe following paternal exposure in pregnancy outcomes. #ACR17 @RheumNow #1312 https://t.co/G4s9zyOhoY
— Dr. Rachel Tate (@uptoTate) November 6, 2017
Crib study shows no detectable levels of CZP on infants umbilical cords#ACR17 @RheumNow pic.twitter.com/7C1ctxv76c
— Julio Gonzalez (@japaoli19) November 7, 2017
Significant reduction in immunosuppression load on uveitis pts with long term ADA use.#ACR17 @RheumNow
#1115 pic.twitter.com/YM2HM0d9sz— Julio Gonzalez (@japaoli19) November 6, 2017
Plenary abst#1787 Landawe presents Atlas 5 study, continuation of ADA is assoc w/ signif less flares in nr-AxSpApts #ACR17 pic.twitter.com/GXgt03aWxT
— Dr. John Cush (@RheumNow) November 6, 2017
#GAMECHANGER TNFI gives more ILD in RA than Abatacept in one study and not in another Not sure why. #acr17 @rheumnow #137 #526
— Janet (@Janetbirdope) November 6, 2017
AxSpA- Does obesity affect response to TNF blockers? #ACR17 #AnkylosingSpondylitis @RheumNow pic.twitter.com/ubmQHTqdVq
— Dr. shashank akerkar (@doctorakerkar) November 6, 2017
UST tops TNFi resolving enthesitis in a small sample of PsA pts. ECLIPSA
#881#ACR17 @RheumNow https://t.co/5AKRP473dD pic.twitter.com/bZOLWsQnIG— Julio Gonzalez (@japaoli19) November 5, 2017
Switching to non-TNF bDMARDs more effective than cycling 2nd line TNFi bDMARDs in TNF-IR pts. #ACR17 @RheumNow #238 https://t.co/RUGisVifAD pic.twitter.com/Q2Ps41CTVR
— Dr. Rachel Tate (@DrRachelTate) November 5, 2017
#ACR17 metaanalysis:Adding MTX to TNFi helps skin scores NOT joints in pts w/PsA @rheumnow #636 pic.twitter.com/2vAQgnYZXp
— k dao (@KDAO2011) November 5, 2017
Dr L Gensler #ACR17: tobacco use decrease efficacy of TNF inhibitors
— k dao (@KDAO2011) November 4, 2017
Reminder slide re Biologics & which diseases they work in #ACR17 pic.twitter.com/4ClkyiqdkO
— Dr Irwin Lim (@_connectedcare) November 4, 2017
My approach:
If primary nonresponse to TNFi -> IL-17.
If secondary nonresponse to TNFi -> 2nd TNFi#ACR17
— Dr. Paul Sufka (@psufka) November 4, 2017
I typically use this 2nd line for those not responding to TNFi in AS. What about you? #ACR17 pic.twitter.com/taFDHiKqhx
— Dr Irwin Lim (@_connectedcare) November 4, 2017
EULAR 2017 TtT recommendations for SpA #ACR17 pic.twitter.com/jMgo29PGQf
— Suleman Bhana, MD (@DrBhana) November 4, 2017
ACR 2016 treatment guidelines for AS/SpA #ACR17 pic.twitter.com/c1kKEMtgKV
— Suleman Bhana, MD (@DrBhana) November 4, 2017